Home Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
Article
Licensed
Unlicensed Requires Authentication

Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA

  • Yuanyuan Xu , Toshiyuki Yamada , Takahiko Satoh and Yasuaki Okuda
Published/Copyright: December 23, 2005

Abstract

Serum amyloid A (SAA), a plasma precursor of reactive amyloid deposits, is a multigene product. SAA1 and SAA2, with primary structures that are 93% identical (98 of 104 amino acids), behave as acute phase proteins, as demonstrated by their increasing levels in plasma. Heretofore, it has been understood that SAA1 predominates and functions as an isotype in plasma. However, accurate measurements differentiating the two isotypes have not been reported. In this study, using monoclonal antibodies specific for SAA1, we developed an enzyme-linked immunosorbent assay (ELISA) for SAA1. The levels and ratios of SAA1 in total SAA (TSAA) were investigated in healthy subjects and patients with rheumatoid arthritis (RA). The SAA1/TSAA ratio was 74±12% and 77±12% in healthy subjects and RA patients, respectively. In RA patients, the ratios were not influenced by SAA1 genotype, which has been proposed to affect plasma SAA values. The kinetics of SAA1 in inflamed patients undergoing hemodialysis was found to be parallel with total SAA and C-reactive protein. Finally, this study confirmed that SAA1 is a major isotype of acute phase SAA and may determine total SAA values. This specific assay could be used in the evaluation of SAA behavior in several clinical conditions.


Corresponding author: Toshiyuki Yamada, MD, Department of Clinical Laboratory Medicine, Jichi Medical School, 3311 Yakushiji, Minamikawachi, Tochigi 329-0498, Japan Phone: +81-285-587386, Fax: +81-285-449947,

References

1. Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA). Biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1994; 1:119–37.10.3109/13506129409148635Search in Google Scholar

2. Sipe JD. Revised nomenclature for serum amyloid A. Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid 1999; 6:67–70.10.3109/13506129908993291Search in Google Scholar

3. Yamada T. Serum amyloid A (SAA). A concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999; 37:381–8.10.1515/CCLM.1999.063Search in Google Scholar

4. Thorn CF, Whitehead AS. Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid A genes, SAA1 and SAA2. J Immunol 2002; 169:399–406.10.4049/jimmunol.169.1.399Search in Google Scholar

5. Strachan AF, de Beer FC, van der Westhuyzen DR, Coetzee GA. Identification of three isoform patterns of human serum amyloid A protein. Biochem J 1988; 250:203–7.10.1042/bj2500203Search in Google Scholar

6. Yamada T, Hirano N, Kuroda T, Okuda Y, Itoh Y. Generation and characterization of rat monoclonal antibodies against human serum amyloid A. Scand J Immunol 1997; 46:175–9.10.1046/j.1365-3083.1997.d01-108.xSearch in Google Scholar

7. Yamada T, Wada A, Itoh Y, Itoh K. Serum amyloid A1 alleles and plasma concentrations of serum amyloid A. Amyloid 1999; 6:199–204.10.3109/13506129909007327Search in Google Scholar

8. Yamada T, Okuda Y, Takasugi K, Itoh K, Igari J. Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60:124–7.10.1136/ard.60.2.124Search in Google Scholar

9. Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD. Fibril formation from recombinant serum amyloid A. Biochim Biophys Acta 1994; 1226:323–9.10.1016/0925-4439(94)90044-2Search in Google Scholar

10. Yamada T, Wada A, Itoh K, Igari J. Serum amyloid A secretion from monocytic leukaemia cell line THP-1 and cultured human peripheral monocytes. Scand J Immunol 2000; 52:7–12.10.1046/j.1365-3083.2000.00734.xSearch in Google Scholar PubMed

11. Yamada T, Uchiyama K, Yakata M, Geiyo F. Sandwich enzyme immunoassay for serum amyloid A protein (SAA). Clin Chim Acta 1989; 179:169–76.10.1016/0009-8981(89)90163-0Search in Google Scholar

12. Yamada T, Wada A. Slower clearance of human SAA1.5 in mice: implications for allele specific variation of SAA concentration in human. Amyloid 2003; 10:147–50.10.3109/13506120308998996Search in Google Scholar PubMed

Received: 2005-4-25
Accepted: 2005-10-24
Published Online: 2005-12-23
Published in Print: 2006-1-1

©2006 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Where does the evidence come from?
  2. NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
  3. Plasma cell-free DNA as an indicator of severity of injury in burn patients
  4. Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
  5. Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
  6. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
  7. APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
  8. Association study between fibronectin and coronary heart disease
  9. Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
  10. Urinary calcium excretion in severe preeclampsia and eclampsia
  11. In vitro re-mineralization of demineralized bone matrix in human serum
  12. Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
  13. Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
  14. Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
  15. Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
  16. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
  17. A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
  18. Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
  19. The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
  20. Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
  21. EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
  22. POX-Act assay and d-ROMs test – what are the facts?
  23. External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
Downloaded on 7.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2006.012/html?lang=en
Scroll to top button